EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

New Gene Signature–Based Prognostic Model for Patients With VEGF‐Overexpressing Esophageal Squamous Cell Carcinoma

Yonghui Li, Ruiyao Wang, Haibo Wang iD, Tingting Li iD, Cheng Long Zhang, Shaoyong Dong, Biao Zhang

BioMed Research International · 2025

DOI: 10.1155/bmri/5694628 ↗

Kurz gefasst

Fachartikel in der Zeitschrift BioMed Research International, 2025. Verfasst von Yonghui Li und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Thoracic Surgery, Affiliated Hospital of Hebei University, Baoding, Hebei, China, hbu.cn. Hauptthemen laut MEDLINE: Esophageal Squamous Cell Carcinoma, Vascular Endothelial Growth Factor A, Esophageal Neoplasms. Die Arbeit nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background and Aims The effects of vascular endothelial growth factor (VEGF) overexpression on the prognosis of patients with esophageal squamous cell carcinoma (ESCC) are still unclear. The aim of this study was to construct and evaluate a mutant gene–based model to predict the prognosis of ESCC patients with VEGF overexpression.

Methods

Samples from 50 ESCC patients with VEGF overexpression were subjected to next‐generation sequencing (NGS) to identify gene mutations. The associations between the enrichment of these mutations and patient outcomes were also evaluated in a cohort from The Cancer Genome Atlas. Hazard ratios were identified via the Kaplan–Meier and Cox analyses. A support vector machine recursive feature elimination algorithm was used to construct the model, and receiver operating characteristic analysis was carried out to evaluate its prognostic performance.

Results

ESCC patients with FAT1 , FGF3 , FGF12 , and FGF19 mutations; advanced M stage; and high neutrophil counts tended to have poorer prognoses.

Conclusion

A model based on a four‐gene signature effectively predicts the prognosis of ESCC patients.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Esophageal Squamous Cell CarcinomaVascular Endothelial Growth Factor AEsophageal NeoplasmsHumansFemaleMalePrognosisMiddle AgedGene Expression Regulation, NeoplasticMutationAgedBiomarkers, TumorKaplan-Meier EstimateHigh-Throughput Nucleotide Sequencing

Stichwörter der Autor:innen

CAFsESCCTCGAVEGFprognosis model

Substanzen

Vascular Endothelial Growth Factor AVEGFA protein, humanBiomarkers, Tumor

Autor:innen und Institutionen

  • Department of Thoracic Surgery, Affiliated Hospital of Hebei University, Baoding, Hebei, China, hbu.cn.

ORCID-Profile: Haibo Wang, Tingting Li

Zitieren

APA

Li, Y., Wang, R., Wang, H., Li, T., Zhang, C. L., Dong, S., & Zhang, B. (2025). New Gene Signature–Based Prognostic Model for Patients With VEGF‐Overexpressing Esophageal Squamous Cell Carcinoma. BioMed Research International. https://doi.org/10.1155/bmri/5694628

Vancouver

Li Y, Wang R, Wang H, Li T, Zhang CL, Dong S, et al. New Gene Signature–Based Prognostic Model for Patients With VEGF‐Overexpressing Esophageal Squamous Cell Carcinoma. BioMed Research International. 2025. doi:10.1155/bmri/5694628

BibTeX
@article{Li2025,
  author = {Li, Yonghui and Wang, Ruiyao and Wang, Haibo and Li, Tingting and Zhang, Cheng Long and Dong, Shaoyong and Zhang, Biao},
  title = {New Gene Signature–Based Prognostic Model for Patients With VEGF‐Overexpressing Esophageal Squamous Cell Carcinoma},
  journal = {BioMed Research International},
  year = {2025},
  doi = {10.1155/bmri/5694628}
}
Kostenlos starten →